Numab Therapeutics AG of Switzerland will use the money generated from an in-licensing deal with Intarcia Therapeutics Inc. to fund its own early-stage proprietary pipeline of innovative antibody-based therapeutics, which it believes has huge commercial potential, the Swiss biotech's co-founder told Scrip.
Founded in 2011, Numab has leveraged its next-generation multi-specific technology to create a pipeline of proprietary antibody-based programs, while also using its platform to discover innovative antibody-based therapeutics on behalf...